Opioid Use Disorder Individuals On Methadone Maintenance Treatment Versus Those Not On Methadone Treatment: A Naturalistic Cross-sectional Comparative Study of Cognitive Performance

2018 ◽  
Author(s):  
Kristian Sant
Keyword(s):  
Comparative Study ◽  
Cognitive Performance ◽  
Methadone Maintenance Treatment ◽  
Maintenance Treatment ◽  
Methadone Maintenance ◽  
Methadone Treatment ◽  
Opioid Use Disorder ◽  
Opioid Use ◽  
Cross Sectional

scholarly journals Cannabis Use Among Patients Attending A Methadone Maintenance Treatment Clinic In Nairobi, Kenya

2020 ◽  
Author(s):  
Elizabeth Wambui Ngarachu ◽  
Sarah Kanana Kiburi ◽  
Frederick R. Owiti ◽  
Rachel N. Kangethe
Keyword(s):  
Methadone Maintenance Treatment ◽  
Maintenance Treatment ◽  
Methadone Maintenance ◽  
Methadone Treatment ◽  
Opioid Use Disorder ◽  
Cannabis Use ◽  
Opioid Use ◽  
Loss To Follow Up ◽  
Treatment Clinic

Abstract Background: Cannabis use is common among patients with opioid use disorder receiving methadone treatment. Research has shown that cannabis use during methadone treatment may impact negatively on treatment outcome. This study aimed at determining the prevalence and pattern of cannabis use and the associated socio-demographic characteristics among patients on methadone treatment. Methods: This was a retrospective study of 984 patients on methadone therapy at a methadone maintenance treatment clinic in Nairobi, Kenya. Data on socio-demographic characteristics and drug use patterns based urine drug screens was collected from patients’ files. Data was analyzed using SPSS for windows version 23.0. Results: Prevalence of cannabis use was 84.8% at baseline and 62.8% during follow up. Polysubstance use pattern was observed with heroin, cannabis and benzodiazepines being the commonest drugs. Majority of cannabis users were male (88.1%), aged 28-37 years (42.2%), unemployed (74.3%), had low level of education (87.7%) and single (72.4%). Cannabis use was associated with loss to follow up (p<0.001). Females were more likely to drop out of treatment and less likely to stop using cannabis during follow up compared to males. Sociodemographic factors associated with reduced risk for cannabis use were; being in older age group 48-57 years (OR 0.51, 95%CI, 0.30-0.87, p=0.013) and university education (OR 0.15, 95%CI, 0.05-0.69, p=0.005) while being in age group 18-27 years and being married were associated with increased risk for cannabis use (OR 2.62,95%CI, 1.78-3.86,p=0.001 and OR 1.50, 95%CI, 1.7-2.10,p=0.021 respectively). Conclusion: There is a prevalence of cannabis use among patients in receiving methadone treatment in Kenya is similar. In addition, cannabis use was associated with loss to follow up and sociodemographic characteristics. Cannabis use screening and targeted interventions for management should be incorporated in methadone treatment programs to improve outcomes for patients on methadone. Key words : cannabis, opioid use disorder, methadone maintenance treatment, Kenya

scholarly journals The association between health conditions and cannabis use in patients with opioid use disorder receiving methadone maintenance treatment

BJPsych Open ◽  
2019 ◽  
Vol 5 (6) ◽  
Author(s):  
Ieta Shams ◽  
Nitika Sanger ◽  
Meha Bhatt ◽  
Tea Rosic ◽  
Candice Luo ◽  
...  
Keyword(s):  
Anxiety Disorders ◽  
Methadone Maintenance Treatment ◽  
Odds Ratio ◽  
Maintenance Treatment ◽  
Methadone Maintenance ◽  
Current Treatment ◽  
Opioid Use Disorder ◽  
Cannabis Use ◽  
Health Conditions ◽  
Opioid Use

Background Cannabis is the most commonly used substance among patients in methadone maintenance treatment (MMT) for opioid use disorder. Current treatment programmes neither screen nor manage cannabis use. The recent legalisation of cannabis in Canada incites consideration into how this may affect the current opioid crisis. Aims Investigate the health status of cannabis users in MMT. Method Patients were recruited from addiction clinics in Ontario, Canada. Regression analyses were used to assess the association between adverse health conditions and cannabis use. Further analyses were used to assess sex differences and heaviness of cannabis use. Results We included 672 patients (49.9% cannabis users). Cannabis users were more likely to consume alcohol (odds ratio 1.46, 95% CI 1.04–2.06, P = 0.029) and have anxiety disorders (odds ratio 1.75, 95% CI 1.02–3.02, P = 0.043), but were less likely to use heroin (odds ratio 0.45, 95% CI 0.24–0.86, P = 0.016). There was no association between cannabis use and pain (odds ratio 0.98, 95% CI 0.94–1.03, P = 0.463). A significant association was seen between alcohol and cannabis use in women (odds ratio 1.79, 95% CI 1.06–3.02, P = 0.028), and anxiety disorders and cannabis use in men (odds ratio 2.59, 95% CI 1.21–5.53, P = 0.014). Heaviness of cannabis use was not associated with health outcomes. Conclusions Our results suggest that cannabis use is common and associated with psychiatric comorbidities and substance use among patients in MMT, advocating for screening of cannabis use in this population. Declaration of interest None.

scholarly journals Adjuvant laser meridian massage in men with opioid use disorder on methadone maintenance treatment

Medicine ◽  
2019 ◽  
Vol 98 (39) ◽  
pp. e17319 ◽  
Author(s):  
Wen-Long Hu ◽  
Meng-Chang Tsai ◽  
Chun-En Kuo ◽  
Chun-Ting Liu ◽  
Szu-Ying Wu ◽  
...  
Keyword(s):  
Methadone Maintenance Treatment ◽  
Maintenance Treatment ◽  
Methadone Maintenance ◽  
Opioid Use Disorder ◽  
Opioid Use

Impulsivity and craving in subjects with opioid use disorder on methadone maintenance treatment

2021 ◽  
Vol 219 ◽  
pp. 108483
Author(s):  
Jun Li ◽  
Kathrin Weidacker ◽  
Alekhya Mandali ◽  
Yingying Zhang ◽  
Seb Whiteford ◽  
...  
Keyword(s):  
Methadone Maintenance Treatment ◽  
Maintenance Treatment ◽  
Methadone Maintenance ◽  
Opioid Use Disorder ◽  
Opioid Use

scholarly journals Take-Home Dosing Experiences among Persons Receiving Methadone Maintenance Treatment During COVID-19

2020 ◽  
Author(s):  
Mary C. Figgatt ◽  
Zach Salazar ◽  
Elizabeth Day ◽  
Louise Vincent ◽  
Nabarun Dasgupta
Keyword(s):  
Methadone Maintenance Treatment ◽  
Maintenance Treatment ◽  
Treatment Guidelines ◽  
Methadone Maintenance ◽  
Methadone Treatment ◽  
List Type ◽  
Opioid Use ◽  
Opioid Treatment ◽  
Life Saving ◽  
Treatment Facilities

AbstractPurposeMethadone maintenance treatment is a life-saving treatment for people with opioid use disorders (OUD). The coronavirus pandemic (COVID-19) introduces many concerns surrounding access to opioid treatment. In March 2020, the Substance Abuse and Mental Health Services Administration (SAMHSA) issued guidance allowing the expansion of take-home methadone doses. We sought to describe changes to treatment experiences from the perspective of persons receiving methadone at outpatient treatment facilities for OUD.MethodsWe conducted an in-person survey among 104 persons receiving methadone from three clinics in central North Carolina in June and July 2020. Surveys collected information on demographic characteristics, methadone treatment history, and experiences with take-home methadone doses in the context of COVID-19 (i.e., before and since March 2020).ResultsBefore COVID-19, the clinic-level percent of participants receiving any amount of days’ supply of take-home doses at each clinic ranged from 56% to 82%, while it ranged from 78% to 100% since COVID-19. The clinic-level percent of participants receiving a take-homes days’ supply of a week or longer (i.e., ≥6 days) since COVID-19 ranged from 11% to 56%. Among 87 participants who received take-homes since COVID-19, only four reported selling their take-home doses.ConclusionsOur study found variation in experiences of take-home dosing by clinic and little diversion of take-home doses. While SAMSHA guidance should allow expanded access to take-home doses, adoption of these guidelines may vary at the clinic level. The adoption of these policies should be explored further, particularly in the context of benefits to patients seeking OUD treatment.HighlightsMethadone take-home dosing of survey participants varied by clinic.Diversion of take-home doses was rare.Implementation of COVID-19 opioid treatment guidelines should be examined further.

Sign in / Sign up

Export Citation Format

Share Document